Clovis Oncology, Inc. (CLVS)
(Delayed Data from NSDQ)
$18.95 USD
+0.51 (2.77%)
Updated May 3, 2019 04:00 PM ET
After-Market: $18.96 (%) 5:22 PM ET
NA Value NA Growth NA Momentum NA VGM
View All Zacks #1 Ranked Stocks
Brokerage Reports
0 items in cart
Clovis Oncology, Inc. [CLVS]
Reports for Purchase
Showing records 1 - 20 ( 238 total )
Company: Clovis Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Price: 5.00
Company: Clovis Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Price: 24.95
Company: Clovis Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Radiopharma Roundup-Recent Devlopment in Radiopharma
Provider: Brookline Capital Markets
Analyst: Research Department
Price: 25.00
Company: Clovis Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Price: 24.95
Company: Clovis Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Price: 24.95
Company: Clovis Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Price: 24.95
Company: Clovis Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Price: 24.95
Company: Clovis Oncology, Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Results; Potential sNDA Submission in 3Q22 for 1L Maintenance Ovarian Cancer; A Need to Raise Additional Capital
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Price: 12.50
Company: Clovis Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Price: 24.95
Company: Clovis Oncology, Inc.
Industry: Medical - Biomedical and Genetics
EMA Recommends Against Use of Rubraca for Third-Line Ovarian Cancer Treatment
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Price: 5.00
Company: Clovis Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Results of Type A Meeting With FDA Regarding ATHENA-MONO Trial sNDA
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Price: 5.00
Company: Clovis Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Price: 24.95
Company: Clovis Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Phase 1 Data for FAP-2286 Presented at SNMMI Annual Meeting
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Price: 12.50
Company: Clovis Oncology, Inc.
Industry: Medical - Biomedical and Genetics
3L BRCA+ Ovarian Cancer Removed from U.S. Rubraca Label
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Price: 5.00
Company: Clovis Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Radiopharma Roundup - Highlights from SNMMI 2022
Provider: Brookline Capital Markets
Analyst: DOLLIVER K
Price: 5.00
Company: Clovis Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Rubraca Monotherapy Data Update in 1L Maintenance Treatment of Ovarian Cancer Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Price: 5.00
Company: Clovis Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Price: 24.95
Company: Clovis Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Price: 24.95
Company: Clovis Oncology, Inc.
Industry: Medical - Biomedical and Genetics
FDA Advises Clovis Not to Submit Rubraca for 1L Maintenance Without OS Data, Timing is Now Uncertain; Lowering Rating
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Price: 12.50
Company: Clovis Oncology, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Results; Rubraca U.S. Sales Disappoint; Phase 3 First- Line Maintenance Data at ASCO; Lowering PT by $1 to $4
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Price: 12.50